×
Pyxis Oncology Total Assets 2021-2025 | PYXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pyxis Oncology total assets from 2021 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Pyxis Oncology Total Assets 2021-2025 | PYXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pyxis Oncology total assets from 2021 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.7B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$46.1B
BeOne Medicines - (ONC)
$31.9B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$8B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B